Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Home
Search
Quick Search
Advanced
Fulltext
Browse
Collections
Persons
My eDoc
Session History
Login
Name:
Password:
Documentation
Help
Support Wiki
Direct access to
document ID:


          Institute: MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut)     Collection: Yearbook_2015     Display Documents



ID: 711926.0, MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut) / Yearbook_2015
Biophysical inhibition of pulmonary surfactant function by polymeric nanoparticles: role of surfactant protein B and C
Authors:Beck-Broichsitter, M.; Ruppert, C.; Schmehl, T.; Gunther, A.; Seeger, W.
Date of Publication (YYYY-MM-DD):2014-11
Title of Journal:Acta Biomater
Volume:10
Issue / Number:11
Start Page:4678
End Page:4684
Audience:Not Specified
Abstract / Description:The current study investigated the mechanisms involved in the process of biophysical inhibition of pulmonary surfactant by polymeric nanoparticles (NP). The minimal surface tension of diverse synthetic surfactants was monitored in the presence of bare and surface-decorated (i.e. poloxamer 407) sub-100 nm poly(lactide) NP. Moreover, the influence of NP on surfactant composition (i.e. surfactant protein (SP) content) was studied. Dose-elevations of SP advanced the biophysical activity of the tested surfactant preparation. Surfactant-associated protein C supplemented phospholipid mixtures (PLM-C) were shown to be more susceptible to biophysical inactivation by bare NP than phospholipid mixture supplemented with surfactant protein B (PLM-B) and PLM-B/C. Surfactant function was hindered owing to a drastic depletion of the SP content upon contact with bare NP. By contrast, surface-modified NP were capable of circumventing unwanted surfactant inhibition. Surfactant constitution influences the extent of biophysical inhibition by polymeric NP. Steric shielding of the NP surface minimizes unwanted NP-surfactant interactions, which represents an option for the development of surfactant-compatible nanomedicines.
Free Keywords:*Biophysical Phenomena; Lactic Acid/chemistry; Nanoparticles/*chemistry; Phospholipids/chemistry; Polymers/chemistry/*pharmacology; Pulmonary Surfactant-Associated Protein B/*antagonists & inhibitors/metabolism; Pulmonary Surfactant-Associated Protein C/*antagonists & inhibitors/metabolism; Pulmonary Surfactants/*antagonists & inhibitors/metabolism; Biophysical inhibition; Hydrophobic surfactant proteins; Polymeric nanoparticles; Pulmonary drug delivery; Pulmonary surfactant
External Publication Status:published
Document Type:Article
Communicated by:MPI für Herz- und Lungenforschung
Affiliations:MPI für physiologische und klinische Forschung
External Affiliations:Medical Clinic II, Department of Internal Medicine, Justus-Liebig-Universitat, Klinikstrasse 33, D-35392 Giessen, Germany. %^ 1435822045
Identifiers:ISSN:1878-7568 (Electronic) 1742-7061 (Linking) %R 10.1016/j.actbio.2014.07.026
URL:http://www.ncbi.nlm.nih.gov/pubmed/25087869
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.